Skip to content

Impact Of Closure Of Patent Foramen Ovale On Apnoea-Hypopnoea-Index, Nocturnal Hypoxemia And Systemic Vascular Function In Patients With Obstructive Sleep Apnoea

Impact Of Closure Of Patent Foramen Ovale On Apnoea-Hypopnoea-Index, Nocturnal Hypoxemia And Systemic Vascular Function In Patients With Obstructive Sleep Apnoea

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01780207
Enrollment
Unknown
Registered
2013-01-30
Start date
Unknown
Completion date
Unknown
Last updated
2014-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Sleep Apnea

Brief summary

The purpose of this study in patients with obstructive sleep apnoea (OSA) and concomitant patent foramen ovale (PFO) is to assess the impact of percutaneous PFO closure on nocturnal hypoxemia and apnea/hypopnea, pulmonary and systemic artery pressure, endothelial function and arterial stiffness.

Interventions

Sponsors

Insel Gruppe AG, University Hospital Bern
Lead SponsorOTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Patients with newly diagnosed moderate to severe OSA * Age \> 17 years * Written informed consent for study participation.

Exclusion criteria

* Patients with other pulmonary disease associated with oxygen desaturation (other than obesity-associated pulmonary restriction) * Patients with central sleep apnea syndrome * Patients with other causes of pulmonary hypertension * Intracardiac shunt other than via PFO * Severe valvular heart disease * Abnormal left ventricular (LV) systolic function (ejection fraction \<50%) * Obesity with BMI \> 40 * Contraindication to TOE * Severe pulmonary arterial hypertension (mean pulmonary artery pressure \> 45 mmHg)

Design outcomes

Primary

MeasureTime frame
Apnea Hypopnea Index (AHI), apnea index (changes from baseline to follow-up)0, 3 months

Secondary

MeasureTime frame
Systemic vascular assessment0, 3 months

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026